Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | MET | P08581 | 3/20 | 0.67 |
| ▸ | AURKA | O14965 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | TEK | Q02763 | 2/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 1/20 | 0.67 |
| ▸ | BRAF | P15056 | 1/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.67 |
| ▸ | FLT4 | P35916 | 1/20 | 0.67 |
| ▸ | AXL | P30530 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747552 | 0.93 | KDR (0.65) | KDRCYP3A4CYP2D6METAURKA | |
| SCHEMBL2747446 | 0.90 | KDR (0.71) | KDRCYP3A4CYP2D6METAURKA | |
| SCHEMBL2747083 | 0.90 | KDR (0.61) | KDRCYP3A4CYP2D6METAURKA | |
| SCHEMBL2747514 | 0.90 | KDR (0.74) | KDRCYP3A4CYP2D6METAURKA | |
| SCHEMBL2748526 | 0.89 | KDR (0.71) | KDRCYP3A4CYP2D6METAURKA | |
| SCHEMBL2749785 | 0.88 | PDGFRA (0.74) | KDRCYP3A4CYP2D6METAURKA | |
| SCHEMBL4548871 | 0.88 | KDR (0.71) | KDRCYP3A4CYP2D6METAURKA | |
| SCHEMBL2747554 | 0.87 | KDR (0.72) | KDRCYP3A4CYP2D6METAURKA | |
| SCHEMBL2747306 | 0.87 | KDR (0.66) | KDRCYP3A4CYP2D6METAURKA | |
| SCHEMBL2747795 | 0.87 | MET (0.75) | KDRCYP3A4CYP2D6METAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007518824-A | — | — | 2007-07-12 | — | — | JP | claimed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | claimed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | claimed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885CYP3A4 348/4885CYP2D6 363/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885CYP3A4 348/4885CYP2D6 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.